Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629525 · ClinicalTrials.gov registry record · Phase 2
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 2 study of Hormone-refractory Prostate Cancer, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00629525 is a Phase 2 study of Hormone-refractory Prostate Cancer that has completed, run by Daniel George, MD. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00629525, a Phase 2 study of Hormone-refractory Prostate Cancer, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
Conditions Studied
Interventions
- DRUG RAD001
Study Locations (1)
North Carolina
- Duke University MEdical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629525
The ClinicalTrials.gov registry entry for NCT00629525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel George, MD, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hormone-refractory Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which RAD001 is the first listed.
NCT00629525 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00629525 about?
NCT00629525 is a clinical study titled "RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer". The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
What is the current status of trial NCT00629525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-08. Estimated completion is 2010-01.
What conditions does trial NCT00629525 study?
This clinical trial studies the following conditions: Hormone-refractory Prostate Cancer.
What interventions are being tested in trial NCT00629525?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00629525?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00629525 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hormone-refractory Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.